stay tuned:
elixi news from the
world

New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis

New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis

EMA has recommended granting an extension of indication to Olumiant (baricitinib) to include the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy. Olumiant is already approved in the European Union to treat moderate to severe active rheumatoid arthritis, a disease causing inflammation of the joints.

Atopic dermatitis (also known as eczema, an itchy red rash of the skin) is a chronic inflammatory skin disease that occurs most frequently in children but also in adults. While in children most cases clear up spontaneously, the disease can persist or start in adulthood. In Europe, it is estimated that up to 7% of adults have atopic dermatitis and the proportion of adults with the moderate to severe form of the disease is approximately 30%. One in four adults with the disease report its onset in adulthood.

Atopic dermatitis causes skin lesions, itchy skin, skin pain, sleep disturbance and is commonly associated with the occurrence of other atopic conditions such as asthma and allergic rhinitis (hay fever). It may lead to difficult-to-control scratching, skin inflammation and infections, functional impairment and mental distress, and feelings of anxiety and depression.

Patients with mild forms of the disease are generally treated with emollients (moisturisers) and topical corticosteroids (creams used to reduce swelling and redness during flare-ups), and/or topical calcineurin inhibitors. However, patients with moderate to severe atopic dermatitis require additional therapies to control their skin inflammation and alleviate the most bothersome symptoms. Systemic treatment options are limited and there is still a need for new treatment options.

Olumiant works by blocking the action of enzymes known as Janus kinases (JAKs) that mediate the pathways involved in the inflammatory process in atopic dermatitis. It is the first JAK inhibitor to treat moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy in the EU and offers a different mode of action to the currently available treatment options. It is the first medicine for moderate as well as severe atopic dermatitis that patients can take orally.

For more information and fast delivery of the life-saving, latest FDA approved oncology drugs, please contact us at info@elixi-int.com

We are a Swiss pharmaceutical wholesaler, specialised in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

 

Share this article

Tweet
Share
Pin it
Share

SEE Also

we are specialized in the procurement and distribution of pharmaceutical products, medical devices all over the world

Stay Tuned

Subscribe to our newsletter

    Headquarter

    Elixi International SA
    Vicolo Oldelli 12
    6830 Chiasso (TI)

    Switzerland

    Tel.  +41 (0)91 6822040
    info@elixi-int.com

    Subsidiary

    Elixi Europe Srl
    Via Uberti 6
    21100 Varese (VA)

    Italy

    Tel.  +41 (0)91 6822040
    europe@elixi-int.com

    Subsidiary

    Elixi Pharma pte. ltd.
    6A  Shenton way #04-01
    Downtown gallery building

    Singapore

    Tel.  +41 (0)91 6822040
    singapore@elixi-int.com

    ELIXI International SA

    Copyright 2023 ELIXI International SA.   |   All Rights Reserved   |   Privacy Policy   |   Cookie Policy